TROVAGENE :: TROVAGENE :: Revolutionary Molecular Diagnostics

Trovagene's new non-invasive urine-based HPV CLIA lab service goes live

3/27/2013

New, non-invasive molecular diagnostic test is easy, fast, and accurate

3/12/2013

Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton Laguna Nigel, in Dana Point, CA

Clinical Testing Services Trovagene offers molecular diagnostic services through its CLIA-certified, CAP-accredited laboratory. This modern facility is backed by a strong foundation in basic research into novel diagnostics and markers and has a growing list of available tests and panels. Find out more »		World-Leading Research Explained As Trovagene's common stock is listed on NASDAQ, CEO Toni Schuh explains how the company is developing novel diagnostics from analysis of nucleic acid markers found in urine. Find out more »
Revolutionary Diagnostic Technology Trovagene's revolutionary transrenal nucleic acid technology is enabling the development of non-invasive ways to detect, quantify and monitor genetic markers and gene mutations through analysis of nucleic acid markers in urine. Find out more »		What are Transrenal Nucleic Acids (TrNAs) ? Scientists at Trovagene were the first to make the simple yet remarkable discovery that circulating cell-free nucleic acids cross the kidney barrier. These transrenal nucleic acids (TrNAs) have enabled new, non-invasive molecular diagnostics. Find out more »

		Bookmark this page to: